Health & Biotech
ASX Health Stocks: Chimeric and Proteomics are making moves to get ready for clinical trials
Health & Biotech
An ageing population is intensifying global health demand and EZZ’s life science brands are already top shelf solutions
Health & Biotech
ASX Health Stocks: ResApp skyrockets 25% after getting buyout offer from US giant Pfizer
Health & Biotech
Dr Boreham’s Crucible: Putting Microba under the microscope
Health & Biotech
Bring it on: PharmAust to start Phase 1 trial after first instalment lands from FightMND
Health & Biotech
ASX Health Stocks: Pro Medicus bags $32m deal, Kazia shows promise in child cancer drug
Health & Biotech
Osteopore makes first shipment to Colombia, the first of many Latin American markets it will pursue
Health & Biotech
Weed Week: Will the US Senate pass the MORE act, and Swiss cannabis wellness spas are a thing
Health & Biotech
Strong Q3 revenue for Wellnex Life with impressive pipeline of new brands and products ahead
Health & Biotech
ASX Health Stocks: AdAlta gets patent in India, RhinoMed starts selling in Canada
Health & Biotech
ASX Health Stocks: Cann to market over-the-counter CBD capsules in Australia
Health & Biotech
Medlab Clinical looks to revolutionise drug delivery for better patient outcomes
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.